Dyne Therapeutics Inc. is a biotechnology company focused on developing targeted therapies for patients with genetically driven diseases. The company was founded in 2018 by Atlas Venture, which is a leading venture capital firm that invests in life sciences, and was based on research done at Harvard University. Dyne Therapeutics is headquartered in Waltham, Massachusetts, and its mission is to use its proprietary technology to create transformative therapies for patients with rare genetic diseases.
The company's proprietary technology platform is called FORCE (Factory Of Repeat Carrier Engineering), which enables the delivery of therapeutic nucleic acids to muscle tissue with high efficiency and specificity. This technology allows the company to target specific muscle tissues and overcome the challenges associated with delivering therapies to muscle tissue, which has been a long-standing problem in the field of gene therapy. By delivering therapeutic nucleic acids to muscle tissue, Dyne Therapeutics hopes to address the underlying cause of certain rare genetic diseases.
Dyne Therapeutics' pipeline includes several preclinical programs targeting rare muscle diseases, including myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Limb-girdle muscular dystrophy type 2B. The company's lead program is focused on developing a therapy for myotonic dystrophy type 1, which is a genetic disorder that affects muscle function and can also cause problems with heart function, respiratory function, and cognitive function.
Dyne Therapeutics has received funding from several leading venture capital firms, including Atlas Venture, Forbion, and RA Capital Management, as well as strategic partnerships with Novo Nordisk and Sarepta Therapeutics. The company completed its initial public offering (IPO) in February 2021, raising $233 million to support the development of its pipeline of targeted therapies for rare genetic diseases. As of April 2023, the company has a market capitalization of approximately $1.5 billion.
Dyne Therapeutics' management team is led by Joshua Brumm, who serves as the company's President and CEO. Mr. Brumm previously held leadership positions at Moderna and Genzyme, and has extensive experience in the field of gene therapy and rare disease drug development. The company's board of directors includes several prominent leaders in the biotechnology industry, including George Golumbeski, former Executive Vice President of Celgene, and Alexis Borisy, co-founder and partner of Third Rock Ventures.